Patent Number | Title | Applicant | Opposition Date |
---|---|---|---|
EP3384049 | Methods Of Associating Genetic Variants With A Clinical Outcome In Patients Suffering From Age-Related Macular Degeneration Treated With Anti-Vegf | REGENERON PHARMACEUTICALS, INC. | Apr 30, 2024 |
EP3597749 | Methods And Compositions For Rna-Directed Target Dna Modification And For Rna-Directed Modulation Of Transcription | CHARPENTIER, EMMANUELLE | Apr 26, 2024 |
EP3911354 | Aav-Mediated Gene Therapy Restoring The Otoferlin Gene | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) | Apr 19, 2024 |
EP3733847 | Composition For Cleaving A Target Dna Comprising A Guide Rna Specific For The Target Dna And Cas Protein-Encoding Nucleic Acid Or Cas Protein, And Use Thereof | TOOLGEN INCORPORATED | Mar 1, 2023 |
EP3464373 | Use Of Anti-Pd-1 Antibody In The Treatment Of Patients With Colorectal Cancer | BRISTOL-MYERS SQUIBB COMPANY | Jul 26, 2022 |
EP3498734 | Combination Of A Pd-1 Antagonist And A Vegfr Inhibitor For Treating Cancer | MERCK SHARP & DOHME CORP. | May 31, 2022 |
EP3401335 | Composition Comprising Antibody That Binds To Domain Ii Of Her2 And Acidic Variants Thereof | GENENTECH, INC. | Mar 22, 2022 |
EP3288980 | Treatment Of Pd-L1-Positive Melanoma Using An Anti-Pd-1 Antibody | BRISTOL-MYERS SQUIBB COMPANY | Dec 10, 2021 |
EP3330370 | Process For Cultivation Of Cho Cells | NOVARTIS AG | Nov 24, 2021 |
EP3616720 | Pharmaceutical Composition For Cancer Treatment | OSAKA UNIVERSITY | Nov 17, 2021 |
Feel free to send us a message here and we will get back to you